GlassScriptPhysician profile
Kayla Matthews
NPI 1205485802
$8,732.72
in general payments reported to CMS, 2019-2025
35 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $424 · 2023: $3,781 · 2024: $1,847 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Consulting Fee: $2,428 · Travel and Lodging: $335 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,705.98 |
| Consulting Fee | $2,427.72 |
| Travel and Lodging | $334.52 |
| Education | $176.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,247.51 | 2022-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,436.60 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,244.26 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $527.14 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $400.30 | 2021-2025 | Glassia, Takhzyro, Aralast |
| Genzyme Corporation | $353.36 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $270.85 | 2021-2025 | |
| Cycle Pharmaceuticals INC | $131.07 | 2024-2025 | Sajazir |
| Optinose US, INC. | $113.68 | 2021-2024 | |
| Biocryst US Sales Co., LLC | $91.21 | 2023-2025 | Orladeyo |
| Amgen INC. | $80.17 | 2021-2022 | |
| Grifols USA, LLC | $78.49 | 2025 | Prolastin-C Liquid, Gamunex-C |
| Pharming Healthcare, INC. | $70.27 | 2024-2025 | Ruconest |
| Kaleo, INC. | $68.61 | 2021-2024 | Auvi-Q |
| Adma Biomanufacturing LLC | $67.68 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $64.67 | 2022-2023 | Gammaplex, Coagadex |
| Csl Behring | $57.43 | 2021-2025 | Haegarda, Andembry |
| Pfizer INC. | $43.25 | 2024 | |
| Sanofi-Aventis U.S. LLC | $34.28 | 2021 | |
| Aimmune Therapeutics, INC. | $32.74 | 2024-2025 | Zenpep |
| Blueprint Medicines Corporation | $31.66 | 2023-2024 | Ayvakit |
| Abbvie INC. | $27.77 | 2023 | |
| Organon LLC | $27.53 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.44 | 2021 | |
| Lundbeck LLC | $26.69 | 2021 | |
| Seqirus USA INC | $26.49 | 2025 | Fluad, Flucelvax |
| Leo Pharma INC. | $25.38 | 2024 | Adbry |
| Eisai INC. | $21.19 | 2024 | |
| Octapharma USA, INC. | $20.19 | 2023 | Cutaquig |
| Biohaven Pharmaceuticals, INC. | $17.00 | 2021 | |
| Lilly USA, LLC | $16.05 | 2025 | Taltz, Ebglyss |
| Alk-Abello, INC | $15.69 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.26 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.